Stock Price & Analysis

Based on the latest market data and analyst updates, here's a comprehensive analysis of ILMN stock:

Technical Analysis The stock is showing significant weakness, currently trading at $104.88 with a -5.56% decline in regular market trading. The RSI-14 reading of 23.64 indicates severely oversold conditions, suggesting potential for a technical bounce, though the overall trend remains bearish.

Recent Catalysts Two major negative catalysts are impacting ILMN:

1. China Risk: China has added Illumina to its unreliable entities list, which could significantly impact the company's operations in China, representing approximately 7% of sales.

2. Analyst Downgrades: Barclays downgraded ILMN to Underweight from Equal Weight with a price target cut to $100 from $130, citing:

• Increasing uncertainty in China
• Rising competition from Roche in the clinical market
• Weaker-than-expected consumables demand

Price Support/Resistance Levels Based on Fibonacci analysis:

• Current Support: $113.82 (Fibonacci S1)
• Next Support: $106.60 (Fibonacci S2)
• Key Resistance: $137.19 (Fibonacci R1)

Analyst Consensus Recent analyst actions show deteriorating sentiment:

• Barclays: Underweight, PT $100
• Citi: Neutral, PT $130
• Guggenheim: Buy, PT lowered to $150
• Canaccord Genuity: Hold, PT lowered to $135

Recommendation SELL. The combination of technical weakness, fundamental challenges in China, and increasing competitive pressures suggests further downside risk. The stock has broken below key support levels and faces multiple headwinds that could continue pressuring the share price toward Barclays' $100 target.

Based on the provided data and recent market analysis, here is the price prediction for ILMN stock in 2025:

ILMN stock is expected to trade around $100-110 by end of 2025, representing a bearish outlook from current levels, primarily due to increased competition from Roche in the clinical market and growing uncertainty in China market. Barclays recently downgraded Illumina to "Underweight" with a $100 price target, citing concerns about management's ability to meet long-term revenue projections amid weaker-than-expected consumables demand. While Piper Sandler maintains a more optimistic view with a $190 price target, the consensus appears to be shifting bearish given mounting headwinds in key markets.

The S1 support level for ILMN Stock is $107.78 ,The R1 resistant level for ILMN Stock is $136.42.

As of the end of day on 2025-02-11, the price of ILMN Stock was $101.49.

The target price for ILMN Stock according to analyst rating is 160.09, with the highest price target at 250.00 and the lowest at 120.00. Analysts have a Moderate Buy rating on ILMN Stock overall.

The market cap of ILMN is $16.7B.

Based on the provided data and recent analyst updates, here's a comprehensive analysis of ILMN's valuation:

Valuation Analysis ILMN appears overvalued based on several key factors:

1. Recent analyst downgrades indicate significant concerns, with Barclays downgrading to Underweight from Equal Weight and reducing price target from $130 to $100. The downgrade cites increasing uncertainty in China, rising competition from Roche, and weaker-than-expected consumables demand.

2. Multiple compression risk exists as the company faces:

• Intensifying competition in clinical markets
• Uncertain China market conditions
• Disappointing elasticity in consumables demand

Technical Indicators The stock shows bearish momentum with declining price trends, suggesting further downside potential.

Analyst Consensus Recent analyst actions paint a cautious picture:

• Barclays: $100 PT (Underweight)
• Morgan Stanley: $150 PT (Hold)
• Citigroup: $165 PT (Hold, downgraded from Strong Buy)
• Piper Sandler: $185 PT (Buy)

The average price target suggests limited upside potential from current levels, with more analysts shifting to neutral/negative stances.

Conclusion ILMN appears overvalued at current levels due to:

• Increasing competitive pressures
• China market uncertainties
• Valuation multiples above historical averages
• Recent analyst downgrades highlighting fundamental challenges
• Technical indicators suggesting continued weakness

Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Based on the provided data and recent market developments, here's the price prediction for ILMN stock by 2030:

ILMN stock is projected to reach $175-185 by 2030, driven by the company's strong genomics technology position despite near-term headwinds from China market uncertainties. The recent Barclays downgrade to Underweight with $100 price target reflects short-term challenges, but long-term growth potential remains intact given Illumina's technological edge in the expanding genomics sector.

The stock could face significant volatility through 2025-2026 due to increasing competition from Roche in the clinical market and China risks, but should recover and grow steadily from 2027-2030 as the global genomics market expands.

ILMN has a total of 10590 employees.